According to a systematic review published in the European Journal of Dermatology, cancer risk associated with UV nail lamps appears low. Nine studies were included in the review, and most of those studies concluded that UV nail lamps did not pose a significant risk factor for the development of skin cancer. However, experimental studies indicated that long-term exposure may increase the risk of skin cancers. Prolonged and repeated exposure to UV nail lamps may pose a low risk of skin cancer, although the available evidence is weak. Patients should be informed about the limited data to make their own decisions, according to the study author, and dermatologists should be updated with the latest evidence to address patients’ concerns about gel manicures.
DermWorld Insights and Inquiries: Lipoid proteinosis’ weak, hoarse cry is crying for targeted therapeutic intervention
Having recently participated in the excellent conference devoted to antisemitism in medicine organized by Heather Milbar at the University of Pennsylvania, I reacquainted myself with Erich Urbach, who described lipoid proteinosis (LP, Urbach-Wiethe disease) with the otolaryngologist Camillo Wiethe in 1929. One of the peculiarities of dermatology is learning the intricacies of diseases you may never encounter. A reasonable question is, “Why bother?” The answers are simple: 1) you will never secure a rare diagnosis if you are not aware of it; 2) learning of the disease may apply to other disorders. This commentary focuses on newer literature devoted to LP. Keep reading!
FDA warns against use or purchase of Skin-Cap aerosol spray products
The FDA is warning consumers to not purchase or use Skin-Cap aerosol spray products because they may contain undisclosed steroids. This product, sold by Chemigroup France, formerly known as Cheminova Laboratories, has been found for sale on skincap.com, amazon.com, and walmart.com. It is marketed as a treatment for psoriasis, seborrheic, eczema, painful lichen, skin redness, dandruff, itching, and irritation of the skin.
FDA testing identified a high-potency glucocorticosteroid in Skin-Cap aerosol spray products that is not disclosed on the label or packaging. Health care professionals and consumers should report adverse events or side effects related to the use of this product to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.
Adverse events among pediatric patients treated with JAK inhibitors
A review published in Pediatric Dermatology highlighted data regarding adverse events associated with use of commercially available JAK inhibitors. The study looked at infections, constitutional symptoms, and increased risks of respiratory, cardiac, vascular, and renal disorders. In pediatric patients, acne was the most common adverse event, accounting for 30.6%. Children had a higher risk of developing blood and lymphatic disorders (neutropenia, thrombocytopenia, anemia, leukopenia, pancytopenia, and myelosuppression in 35.2%) and viral, fungal, or bacterial infections (21.7%). Adults had a higher risk of developing nervous system and musculoskeletal/connective tissue disorders.
Efficacy and tolerability of a 2.6% benzoyl peroxide cleanser in patients with acne and sensitive skin
In a study published in the Journal of Drugs in Dermatology, the authors assessed the efficacy and safety of a 2.6% benzoyl peroxide cleanser in mild-to-moderate acne vulgaris. Patients with self-perceived sensitive skin and mild-to-moderate acne applied a 2.6% benzoyl peroxide cleanser (complexion-clearing acne vulgaris cleanser) twice daily for four weeks. The total acne vulgaris lesion counts significantly decreased by week one (-25.2%); however, at week four, the lesion count decreased numerically but not significantly. The cleanser was well tolerated, and patients reported good satisfaction.
Emerging fungal infection spread via sexual contact
A recent issue of the CDC’s Morbidity and Mortality Weekly Report discussed four patients with trichophyton mentagrophytes genotype VII (TMVII) infections, a type of ringworm, that were diagnosed during April-July 2024 in New York City among men who have sex with men. In these cases, TMVII infections were more likely to affect anogenital regions, and may involve pain and inflammation, the authors noted. Samples were taken to confirm TMVII through specialized molecular testing. While most ringworm infections can be treated with a topical antifungal and resolve within a few days to a week, infections with TMVII may require prolonged treatment with oral antifungal therapy. Terbinafine appears effective against TMVII in the majority of cases.
Clinicians should be aware of TMVII and consider prescribing oral terbinafine therapy for patients based on clinical features and possible exposures while waiting for confirmatory laboratory diagnosis, according to the report. Clinicians should counsel patients to be aware that TMVII is an emerging fungal infection spread through sex. Authors cautioned against sharing personal items and skin-to-skin contact, including intimate or sexual contact, with anyone known or suspected to have a TMVII infection until they have been treated and the rash has cleared. As these are among the first reported cases in the United States, they highlight the need for vigilance, early diagnosis, and appropriate treatment to prevent further transmission.
Trichophyton indotineae, previously called Trichophyton mentagrophytes genotype VIII, is a separate emerging dermatophyte infection, typically resistant to standard antifungal therapies.
View the Academy’s Emerging Diseases Resource Center, which contains scientific resources to assist in recognition, management, and reporting of emerging threats, including Trichophyton indotineae, mpox, and other dermatophytes of concern. We encourage dermatologists to consider reporting cases, both to the registry and working in conjunction with their local department of health.
Advertisement
The American Academy of Dermatology is a non-profit professional organization and does not endorse companies or products. Advertising helps support our mission.
